Type:Capsule
Generic Name:Cefaclor
Manufacturer:Eskayef Pharmaceuticals Ltd.
Price:৳30.00
Pneumonia, Meningitis, Peritonitis, Otitis media, Septicaemia, Biliary-tract infections, Urinary-tract infections, Skin and skin structure infections, Upper and lower respiratory tract infections, Pharyngitis, Tonsillitis
May be taken with or without food.
Oral Urinary tract infections, Upper and lower respiratory tract infections, Skin infections, Otitis media Adult: As monohydrate: 250-500 mg every 8 hr. Max: 4 g daily.
Oral Urinary tract infections, Upper and lower respiratory tract infections, Skin infections, Otitis media Child: PO 20–40 mg/kg/day, max 1 g/day q12h 1-5 yr: 125 mg tid, >5 yr: 250 mg tid. Suspension & Paediatric Drops: 1 month - 1 year 2.5 ml t.i.d. 0.625 ml t.i.d 1 year - 5 year 5 ml t.i.d. 1.25 ml t.i.d over 5 years 10 ml t.i.d 2.5 ml t.i.d
Renal Impairment CrCl: 10-50 mL/min: Half to full dose CrCl: <10 mL/min: Half dose
Known hypersensitivity to cephalosporins.
Cefaclor binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. It has bactericidal activity against gm-ve bacteria including E. coli, S. pneumoniae, N. gonorrhoea, P. mirabilis and H. influenzae.
Severe renal impairment; history of allergy to penicillin; pregnancy, lactation. Lactation: enters breast milk; use with caution
1-10% Diarrhea (3%),Increased transaminases (3%),Eosinophilia (2%),Moniliasis (2%),Vaginitis (2%),Rash (maculopapular, erythematous, or morbiliform) (1-2%) <1% Stevens-Johnson syndrome,Pseudomembranous colitis,Nausea,Vomiting,Anemia,Neutropenia,Jaundice Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
Pregnancy No adequate and well-controlled studies in pregnant women Because animal reproduction studies are not always predictive of human response, cefaclor should be used during pregnancy only if necessary Lactation Effect on nursing infants is unknown; exercise caution when cefaclor is administered to a nursing woman Extended-release tablets No studies in lactating women performed; small amounts of cefaclor (?0.21 mcg/mL) detected in human milk following administration (single 500-mg dose of cefaclor extended-release tablets)
May enhance the nephrotoxic effect of aminoglycosides. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. Concomitant use w/ warfarin may increase prothrombin time. Probenecid inhibits renal excretion of cefaclor.
